{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,1]],"date-time":"2026-02-01T05:03:25Z","timestamp":1769922205820,"version":"3.49.0"},"reference-count":41,"publisher":"Wiley","issue":"5","license":[{"start":{"date-parts":[[2017,3,9]],"date-time":"2017-03-09T00:00:00Z","timestamp":1489017600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["European J of Haematology"],"published-print":{"date-parts":[[2017,5]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Despite an improved understanding of disease biology and the use of multi\u2010agent chemotherapy, the long\u2010term survival of adults with B\u2010cell acute lymphoblastic leukemia (B\u2010ALL) ranges from 35% to 50%. Management of patients with relapsed B\u2010ALL, a group characterized by dismal outcomes, poses a clinical challenge. To address this unmet need, novel therapeutics are being investigated in the setting of relapsed B\u2010ALL with encouraging results. CD22 is an important B\u2010cell antigen expressed in 80\u201090% of B\u2010ALL cases. CD22 undergoes constitutive endocytosis with antibody ligation, making it an attractive biologic target for immunoconjugates. Inotuzumab ozogamicin (IO), a CD22\u2010targeted antibody\u2010drug conjugate demonstrated impressive single agent activity even among heavily pretreated relapsed B\u2010ALL patients. A recent randomized phase III clinical trial demonstrates superiority of IO over standard of care chemotherapy as first\u2010 or second\u2010line salvage therapy for relapsed B\u2010ALL. In this review, we summarize the preclinical and clinical data available to date using IO in relapsed B\u2010ALL.<\/jats:p>","DOI":"10.1111\/ejh.12862","type":"journal-article","created":{"date-parts":[[2017,2,2]],"date-time":"2017-02-02T15:39:20Z","timestamp":1486049960000},"page":"425-434","source":"Crossref","is-referenced-by-count":46,"title":["Inotuzumab ozogamicin in relapsed B\u2010cell acute lymphoblastic leukemia"],"prefix":"10.1111","volume":"98","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-4216-1414","authenticated-orcid":false,"given":"Swapna","family":"Thota","sequence":"first","affiliation":[{"name":"Department of Hematology\/Oncology Cleveland Clinic Taussig Cancer Institute  Cleveland OH USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Anjali","family":"Advani","sequence":"additional","affiliation":[{"name":"Department of Hematology\/Oncology Cleveland Clinic Taussig Cancer Institute  Cleveland OH USA"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2017,3,9]]},"reference":[{"key":"e_1_2_6_2_1","doi-asserted-by":"publisher","DOI":"10.3322\/caac.21332"},{"key":"e_1_2_6_3_1","unstructured":"HowladerN NooneAM KrapchoM et\u00a0al. (eds).SEER cancer statistics review 1975\u20102013 National Cancer Institute.Bethesda MD http:\/\/seer.cancer.gov\/csr\/1975_2013\/ based on November 2015 SEER data submission posted to the SEER web site April 2016. Last accessed 1 December 2016"},{"key":"e_1_2_6_4_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2010.30.7405"},{"key":"e_1_2_6_5_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM199806043382304"},{"key":"e_1_2_6_6_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2011.37.8018"},{"key":"e_1_2_6_7_1","doi-asserted-by":"publisher","DOI":"10.1038\/leu.2009.256"},{"key":"e_1_2_6_8_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2012-05-378943"},{"key":"e_1_2_6_9_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2008.18.6916"},{"key":"e_1_2_6_10_1","doi-asserted-by":"crossref","first-page":"3903","DOI":"10.1182\/blood.V122.21.3903.3903","article-title":"Frontline\u2010treatment of acute lymphoblastic leukemia (ALL) in older adolescents and young adults (AYA) using a pediatric regimen is feasible: toxicity results of the prospective US Intergroup Trial C10403 (Alliance)","volume":"122","author":"Advani AS","year":"2013","journal-title":"Blood"},{"key":"e_1_2_6_11_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2005-04-1623"},{"key":"e_1_2_6_12_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2006-05-018192"},{"key":"e_1_2_6_13_1","doi-asserted-by":"publisher","DOI":"10.1038\/sj.leu.2404824"},{"key":"e_1_2_6_14_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2011-12-399287"},{"key":"e_1_2_6_15_1","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-15-0612"},{"key":"e_1_2_6_16_1","doi-asserted-by":"publisher","DOI":"10.3109\/10428194.2010.529206"},{"key":"e_1_2_6_17_1","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.154.9.4466"},{"key":"e_1_2_6_18_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.molimm.2006.05.007"},{"key":"e_1_2_6_19_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2012.43.0132"},{"key":"e_1_2_6_20_1","doi-asserted-by":"publisher","DOI":"10.1146\/annurev.immunol.15.1.481"},{"key":"e_1_2_6_21_1","doi-asserted-by":"publisher","DOI":"10.2174\/1381612003398564"},{"key":"e_1_2_6_22_1","doi-asserted-by":"publisher","DOI":"10.1126\/science.3240341"},{"key":"e_1_2_6_23_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1471-4892(03)00083-3"},{"key":"e_1_2_6_24_1","doi-asserted-by":"publisher","DOI":"10.1021\/bc010021y"},{"key":"e_1_2_6_25_1","doi-asserted-by":"publisher","DOI":"10.1038\/leu.2011.206"},{"key":"e_1_2_6_26_1","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.28136"},{"key":"e_1_2_6_27_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1349-7006.2012.02241.x"},{"key":"e_1_2_6_28_1","doi-asserted-by":"publisher","DOI":"10.1208\/s12248-016-9929-7"},{"key":"e_1_2_6_29_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2003-07-2466"},{"key":"e_1_2_6_30_1","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-04-1134"},{"key":"e_1_2_6_31_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2009.25.1900"},{"key":"e_1_2_6_32_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2012.42.7211"},{"key":"e_1_2_6_33_1","doi-asserted-by":"publisher","DOI":"10.3109\/10428194.2015.1017821"},{"key":"e_1_2_6_34_1","doi-asserted-by":"publisher","DOI":"10.1038\/sj.leu.2404866"},{"key":"e_1_2_6_35_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(11)70386-2"},{"key":"e_1_2_6_36_1","doi-asserted-by":"publisher","DOI":"10.1002\/pbc.24721"},{"key":"e_1_2_6_37_1","doi-asserted-by":"crossref","first-page":"2255","DOI":"10.1182\/blood.V124.21.2255.2255","article-title":"A phase II Study of Weekly Inotuzumab Ozogamicin (InO) in adult patients with CD22\u2010positive acute lymphoblastic leukemia (ALL) in second or later salvage","volume":"124","author":"Advani AS","year":"2014","journal-title":"Blood"},{"key":"e_1_2_6_38_1","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1182\/asheducation-2010.1.13","article-title":"Treating the \u201colder\u201d adult with acute lymphoblastic leukemia","volume":"2010","author":"Marks DI","year":"2010","journal-title":"Hematology Am Soc Hematol Educ Program"},{"issue":"5","key":"e_1_2_6_39_1","doi-asserted-by":"crossref","first-page":"abstr 7019","DOI":"10.1200\/jco.2014.32.15_suppl.7019","article-title":"Inotuzumab ozogamicin (IO) in combination with low\u2010intensity chemotherapy as front\u2010line therapy for older patients (pts) and as salvage therapy for adult with R\/R acute lymphoblastic leukemia (ALL)","volume":"32","author":"Jabbour E","year":"2014","journal-title":"J Clin Oncol"},{"key":"e_1_2_6_40_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1509277"},{"key":"e_1_2_6_41_1","doi-asserted-by":"publisher","DOI":"10.1002\/ajh.23901"},{"key":"e_1_2_6_42_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.clml.2012.12.003"}],"container-title":["European Journal of Haematology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fejh.12862","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/ejh.12862","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,10,3]],"date-time":"2023-10-03T20:54:53Z","timestamp":1696366493000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/ejh.12862"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,3,9]]},"references-count":41,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2017,5]]}},"alternative-id":["10.1111\/ejh.12862"],"URL":"https:\/\/doi.org\/10.1111\/ejh.12862","archive":["Portico"],"relation":{},"ISSN":["0902-4441","1600-0609"],"issn-type":[{"value":"0902-4441","type":"print"},{"value":"1600-0609","type":"electronic"}],"subject":[],"published":{"date-parts":[[2017,3,9]]}}}